{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(8)"],"submitter":["Lowentritt BH"],"funding":["Blue Earth Diagnostics"],"pubmed_abstract":["<h4>Purpose</h4><sup>18</sup>F-Flotufolastat (<sup>18</sup>F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated <sup>18</sup>F-flotufolastat in men with suspected PCa recurrence. Here, we present results of predefined exploratory endpoints from SPOTLIGHT to evaluate the impact of clinical factors on <sup>18</sup>F-flotufolastat detection rates (DR).<h4>Methods and materials</h4>The impact of baseline prostate-specific antigen (PSA), PSA doubling time (PSAdt), and International Society of Urologic Pathology Grade Group (GG) on <sup>18</sup>F-flotufolastat DR was evaluated among all SPOTLIGHT patients with an evaluable scan, with DR stratified"],"journal":["Advances in radiation oncology"],"pagination":["101532"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11298587"],"repository":["biostudies-literature"],"pubmed_title":["Impact of Clinical Factors on <sup>18</sup>F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study."],"pmcid":["PMC11298587"],"pubmed_authors":["Chapin BF","Helfand BT","Chau A","Uchio EM","Lowentritt BH","SPOTLIGHT Study Group","Michalski JM","Morris MA","Schuster DM","Davis P","Jani AB"],"additional_accession":[]},"is_claimable":false,"name":"Impact of Clinical Factors on <sup>18</sup>F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study.","description":"<h4>Purpose</h4><sup>18</sup>F-Flotufolastat (<sup>18</sup>F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated <sup>18</sup>F-flotufolastat in men with suspected PCa recurrence. Here, we present results of predefined exploratory endpoints from SPOTLIGHT to evaluate the impact of clinical factors on <sup>18</sup>F-flotufolastat detection rates (DR).<h4>Methods and materials</h4>The impact of baseline prostate-specific antigen (PSA), PSA doubling time (PSAdt), and International Society of Urologic Pathology Grade Group (GG) on <sup>18</sup>F-flotufolastat DR was evaluated among all SPOTLIGHT patients with an evaluable scan, with DR stratified","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-22T21:49:21.28Z","creation":"2024-11-09T01:55:08.406Z"},"accession":"S-EPMC11298587","cross_references":{"pubmed":["39104875"],"doi":["10.1016/j.adro.2024.101532"]}}